Mechanism of in Vitro and in vivo Models of Osteoporosis Regulation by Active Ingredients of Traditional Chinese Medicine： A Review
10.13422/j.cnki.syfjx.20241336
- VernacularTitle:中药有效成分调控骨质疏松症体内外模型相关机制研究进展
- Author:
Ming YANG
1
;
Jinji WANG
1
;
Xuefeng ZHUANG
1
;
Xiaolei FANG
1
;
Zhijie ZHU
2
;
Huiwei BAO
1
;
Lijing LI
1
Author Information
1. School of Pharmaceutical Sciences，Changchun University of Chinese Medicine，Changchun 130117，China
2. Tonghua Golden-horse Group Co.Ltd.，Tonghua 134100，China
- Publication Type:Journal Article
- Keywords:
osteoporosis;
active ingredients of traditional Chinese medicine;
oxidative stress;
inflammation;
mechanism
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(3):281-289
- CountryChina
- Language:Chinese
-
Abstract:
Osteoporosis is a common bone disease， whose incidence is still on the rise， posing great challenges to patients and society. This review mainly studies the pathogenesis of osteoporosis from the aspects of oxidative stress， inflammatory response， and glucolipotoxicity-induced injury and clarifies the efficacy and mechanism of some active ingredients of traditional Chinese medicine against osteoporosis through the integration of in vitro and in vivo experiments. The experimental results suggest that some active ingredients can improve bone resorption markers and maintain bone homeostasis by modulating inflammation， oxidative stress， etc. These active ingredients regulate osteoporosis through the receptor activator of nuclear transcription factor-κB （NF-κB） ligand （RANKL） pathway， osteoprotegerin （OPG） pathway， Wnt/β-catenin pathway， NF-κB pathway， mitogen-activated protein kinase （MAPK） pathway， adenosine monophosphate （AMP）-activated protein kinase （AMPK）/mammalian target of rapamycin （mTOR） pathway， and oxidative stress pathway. This review provides ideas for the progress of the prevention and treatment of osteoporosis with the active ingredients of traditional Chinese medicine， aiming to provide new potential lead compounds and reference for the development of innovative drugs and clinical therapy for the treatment of osteoporosis.
